Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about GENB, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| GB-0895 | Severe Asthma | Phase 3 · NCT07359846 | Recruiting |
| GB-0669 | SARS CoV-2 | Phase 1 · NCT07050511 | Completed |
| Anti-MMAE Monoclonal Antibody GB-4362 | Advanced Urothelial Cancer | Phase 1 · NCT07484022 | Recruiting |
| Autologous Anti-MUC16 CAR-BBz-IL-18-expressing… | Platinum-resistant Ovarian Cancer | Phase 1 · NCT07489287 | Recruiting |
| GB-7624 | Atopic Dermatitis (AD) | Phase 1 · NCT06920693 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not GENB's own candidates): Enfortumab Vedotin, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
GENB holds $404.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $56.4M/quarter from operations, an estimated runway of 21.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 11 · Low
Upon closing of the IPO and receipt of the associated cash proceeds, the Company has alleviated the substantial doubt that previously existed, and based on the Company’s current capital resources, which consist of its cash, cash equivalents and marketable securities on hand at September 30, 2026 , together with the $…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GENB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Noubar Afeyan Director, 10% owner · +29,561 options |
Insider | 62,701,915 | 48.57% | 2026-03-31 |
| FMR LLC | Institution (13G, 5%+) | 7,186,203 | 5.57% | 2026-09-30 |
| Michael Nally Chief Executive Officer, Director · +844,595 options |
Insider | 6,919,051 | 5.36% | 2026-03-31 |
| Pioneering Medicines 02, LLC 10% owner |
Insider | 1,562,500 | 1.21% | 2026-03-02 |
| Stephane Bancel Director · +29,561 options |
Insider | 1,184,989 | 0.92% | 2026-02-26 |
| Gevorg Grigoryan Chief Technology Officer · +196,368 options |
Insider | 659,973 | 0.51% | 2026-02-26 |
| Frances Arnold Director · +29,561 options |
Insider | 452,535 | 0.35% | 2026-10-29 |
| Jane L Mendillo Director · +29,561 options |
Insider | 1,500 | 0.00% | 2026-02-26 |
| Jason Silvers President & CFO · +274,493 options Includes shares also reported by Jane L Mendillo, counted once |
Insider | 1,500 | 0.00% | 2026-02-26 |
| Beth Grous Chief People Officer · +114,020 options |
Insider | 300 | 0.00% | 2026-02-26 |
Share count 129,096,666 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GENB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →